November 19, 2025 a 08:00 am
VRTX: Fundamental Ratio Analysis - Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a leading biotechnology company, consistently exhibits strong performances in developing therapies for cystic fibrosis. With their robust pipeline and significant market presence, the company's innovative treatments have garnered positive attention from the market. Investors have shown confidence in VRTX due to its strategic collaborations and promising clinical trials.
Fundamental Rating
Vertex Pharmaceuticals has shown a strong overall score, indicating a stable financial health and growth potential.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
The historical ratings showcase a consistent performance over the recent past periods.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | PE | PB |
|---|---|---|---|---|---|---|---|
| 2025-11-18 | 4 | 5 | 4 | 5 | 2 | 2 | 2 |
| Previous | 0 | 5 | 4 | 5 | 2 | 2 | 2 |
Analyst Target Prices
Analyst estimates for the stock highlight strong potential for growth, with a consensus buy rating.
| High | Low | Median | Consensus |
|---|---|---|---|
| 553 | 414 | 467 | 470.4 |
Analyst Sentiments
The recommendation trends indicate a predominantly bullish outlook among analysts.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 40 | |
| Hold | 14 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Vertex Pharmaceuticals presents a compelling investment opportunity, with consistent growth potential backed by promising clinical trials and strategic partnerships. While current valuations are favorable, potential risks include market competition and regulatory challenges. Overall, analyst sentiments and target prices indicate a positive outlook, aligning well with the company's strong performance record and innovation in the field of cystic fibrosis treatment.